Can a sirolimus-eluting iron bioresorbable scaffold treat coronary artery disease patients with myocardial ischemia?
Patients with coronary artery disease and myocardial ischemia need treatments that keep blood flowing well to the heart. A specific new device called a sirolimus-eluting iron bioresorbable scaffold was tested against standard metallic stents. Research shows this new scaffold actually had worse results than the standard option.
What the research says
A large randomized trial called IRONMAN-II compared the iron scaffold to standard metallic cobalt chromium stents in patients with myocardial ischemia 3. The main goal was to see how much the treated artery narrowed over two years, known as late lumen loss. The study found that the iron scaffold had higher late lumen loss than the standard metallic stents 1.
What to ask your doctor
- What are the risks of higher late lumen loss with the iron scaffold compared to standard stents?
- Are there other bioresorbable options that have shown better results in trials?
- How does the standard metallic stent perform for my specific case of myocardial ischemia?
- What are the long-term safety outcomes for the iron scaffold versus the metallic stent?
This question is drawn from common patient questions about Cardiology and answered using cited medical research. We do not provide individualized advice.